36052-26-3

Usage

Chemical Properties

White to off-white powder

InChI:InChI=1/C7H8N2O2/c1-11-7(10)5-3-2-4-6(8)9-5/h2-4H,1H3,(H2,8,9)

Upstream product

• 26893-72-1 6-acetamido-picolinic acid 
• 88061-85-2 methyl 3-nitroimidazo<1,2-a>pyridine-5-carboxylate 
• 67-56-1 methanol 
• 23628-31-1 6-aminopicolinic acid 
• 118267-40-6 C₁₁H₁₄N₂O₃ 
• 5453-67-8 2,6-bis(methoxycarbonyl)pyridine 
• 1262043-88-8 methyl 6-(benzyloxycarbonylamino)-pyridine-2-carboxylate 
• 499-83-2 Pyridine-2,6-dicarboxylic acid 
• 7170-36-7 6-(methoxycarbonyl)pyridine-2-carboxylic acid 
• 94111-79-2 methyl 6-(chlorocarbonyl)picolinate 
• 13538-41-5 6-aminopyridine-2-carboxamide 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 5327-33-3 2-acetylamino-6-methylpyridine 
• 88047-55-6 methyl imidazo<1,2-a>pyridine-5-carboxylate 

Downstream Products

• 98953-28-7 6-acetylamino-pyridine-2-carboxylic acid methyl ester 
• 13538-41-5 6-aminopyridine-2-carboxamide 
• 178876-83-0 methyl 6-amino-3-bromo-pyridine-2-carboxylate 
• 178876-82-9 6-amino-5-bromo-pyridine-2-carboxylic acid methyl ester 
• 178876-86-3 methyl 5-bromo-6-oxo-1,6-dihydropyridine-2-carboxylate 
• 178876-84-1 6-Acetylamino-5-bromo-pyridine-2-carboxylic acid methyl ester 
• 111753-15-2 methyl 3-aminoimidazo<1,2-a>pyridine-5-carboxylate 
• 88061-85-2 methyl 3-nitroimidazo<1,2-a>pyridine-5-carboxylate 
• 79651-64-2 (6-Amino-pyridin-2-yl)-methanol 
• 1262043-88-8 methyl 6-(benzyloxycarbonylamino)-pyridine-2-carboxylate 
• 1309611-47-9 C₂₀H₁₆N₄O₅ 
• 1309750-78-4 C₂₇H₂₂N₆O₆ 
• 1313028-58-8 C₂₈H₂₄N₆O₇ 
• 1309750-79-5 C₃₃H₂₆N₈O₇ 

Relevant academic research and scientific papers

POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES

The present invention discloses compounds according to Formula I: Wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

Discovery of highly reactive peptide tag by ELISA-type screening for specific cysteine conjugation

We report the discovery of a highly reactive peptide tag for the specific cysteine conjugation of proteins. Screening of cysteine-containing peptides using ELISA-type screening yielded a 19-amino acid tag (DCPPPDDAADDAADDAADD), named DCP3 tag, which enabl

NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR

[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. ????????R1-R2-R3-R4?????(A)

Cation-halide transport through peptide pores containing aminopicolinic acid

Synthetic pores that selectively transport ions of biological significance through membranes could be potentially used in medical diagnostics or therapeutics. Herein, we report cation-selective octapeptide pores derived from alanine and aminopicolinic acid. The ion transport mechanism through the pores has been established to be a cation-chloride symport. The cation-chloride co-transport is biologically essential for the efficient functioning of the central nervous system and has been implicated in diseases such as epilepsy. The pores formed in synthetic lipid bilayers do not exhibit any closing events. The ease of synthesis as well as infinite lifetimes of these pores provides scope for modifying their transport behaviour to develop sensors.

TRISUBSTITUTED HETEROCYCLIC DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides trisubstituted heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; (I) in which R1, R2, R3, Ra, X, L, m and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the trisubstituted heterocyclic derivatives of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Synthesis, structural investigation and computational modelling of water-binding aquafoldamers

Detailed studies on water-binding aquafoldamers are presented that illustrate the potential use of the elongated larger aquafoldamers for recognizing larger water clusters of diverse topologies. A novel self-trapping dimerization mode involving two tetramer molecules is proposed, which is consistent with the obtained varying experimental evidences. The Royal Society of Chemistry 2012.

GAMMA SECRETASE MODULATORS

The invention relates to compounds of formula wherein R1, R1′, R2, R3, n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

GAMMA SECRETASE MODULATERS

The invention relates to compounds of formula ( I ) wherein R1/R1' are independently from each other hydrogen, halogen, lower alkoxy or cyano; R2 is lower alkyl, halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by OR, =0, -C(O)O-lower alkyl, -C(O)NH-lower alkyl, cyano, CH2-O-lower alkyl, cycloalkyl, NRR'or is -O-(CH2)o-phenyl optionally substituted by halogen, or is -(CH2)o-phenyl optionally substituted by one, two or three substituents, selected from halogen, -(CH2)o-cyano, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, C(O)H, -CH2-NH2-, -CH2-NH-C(O)O-lower alkyl, -CH2-NH-C(O)-lower alkyl, -CH2-NH-lower alkyl, -CH2-NH-S(O)2-lower alkyl, lower alkoxy or by lower alkoxy substituted by halogen, or is -(CH2)o-cycloalkyl, or is -(CH2)o-heterocycloalkyl which is optionally substituted by halogen, CF3, lower alkyl, -CH2CN, -C(O)-lower alkyl, -C(O)O-lower alkyl or S(O)2-lower alkyl, or is heteroaryl selected from the group consisting of furanyl, pyrazinyl, pyridinyl, benzooxazolyl or benzoimidazolyl which are optionally substituted by lower alkyl, or is 4-methyl-3,4-dihydro-2H-benzo[l,4]oxazine R and R' are independently from each other hydrogen or lower alkyl, and o is 0 or 1; R3 may occur once or twice and is lower alkyl; A is Formula a), b), c), d), e), f), h), i), j) and Formula k); R2' is hydrogen, lower alkyl, lower alkyl substituted by halogen, C(O)-lower alkyl, S(O)2-lower alkyl or phenyl optionally substituted by halogen; hetaryl is a 5 or 6 membered N, S or O-containing heteroaryl group; n is O, 1, 2 or 3; if n is 2 or 3, R2 may be the same or not; or to pharmaceutically active acid addition salts thereof. The present compounds of formula ( I ) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica and Down syndrome.

HETEROARYL SUBSTITUTED PIPERIDINES

The invention relates to compounds of formula where hetaryl I, hetaryl II, R1,R2,R3, R4, m, n, and o are as defined in the specification or to pharmaceutically active acid addition salts thereof. The compounds of formula I are modulators for amyloid beta and thus may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.